Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus - A randomized clinical trial

Clinical Immunology

Volumn 161, Issue 2, 2015, Pages 217-224

  Treiber, Gerlies ^a   Prietl, Barbara ^a   Fröhlich Reiterer, Elke ^a   Lechner, Evelyne ^a   Ribitsch, Anja ^a   Fritsch, Maria ^b   Rami Merhar, Birgit ^b   Steigleder Schweiger, Claudia ^c   Graninger, Winfried ^a   Borkenstein, Martin ^a   Pieber, Thomas R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Cholecalciferol; Randomized controlled trial; Regulatory T cells; Suppressive capacity; Type 1 diabetes; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; C PEPTIDE; CALCIUM; COLECALCIFEROL; CREATININE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 7 RECEPTOR; PARATHYROID HORMONE; PLACEBO; TRANSCRIPTION FACTOR FOXP3; VITAMIN;

ABSENCE OF SIDE EFFECTS; ADAPTIVE IMMUNITY; ADOLESCENT; APOPTOSIS; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CREATININE URINE LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOMODULATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LOADING DRUG DOSE; LYMPHOCYTE FUNCTION; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; T CELL CULTURE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFECTS; IMMUNOLOGY; MULTICENTER STUDY; PILOT STUDY; TIME; TREATMENT OUTCOME;

ADOLESCENT; C-PEPTIDE; CHILD; CHOLECALCIFEROL; DIABETES MELLITUS, TYPE 1; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 84942600318     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.08.002     Document Type: Article

References (47)

1. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787. 10.1016/j.cell.2008.05.009.
2. Ochs H.D., Gambineri E., Torgerson T.R. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 2007, 38:112-121. 10.1007/s12026-007-0022-2
3. Xavier-da-Silva M.M., Moreira-Filho C.A., Suzuki E., et al. Fetal-onset IPEX: report of two families and review of literature. Clin. Immunol. 2015, 156:131-140. 10.1016/j.clim.2014.12.007
4. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 2010, 10:849-859. 10.1038/nri2889
5. Putnam A.L., Vendrame F., Dotta F., Gottlieb P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J. Autoimmun. 2005, 24:55-62. 10.1016/j.jaut.2004.11.004
6. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-Cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
7. Lindley S., Dayan C.M., Bishop A., et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
8. Schneider A., Rieck M., Sanda S., et al. The effector T cells of diabetic subjects are resistant to regulation via CD4+FOXP3+ regulatory T cells. J. Immunol. 2008, 181:7350-7355.
9. Lawson J.M., Tremble J., Dayan C., et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 2008, 154:353-359. 10.1111/j.1365-2249.2008.03810.x
10. Tooley J.E., Waldron-Lynch F., Herold K.C. New and future immunomodulatory therapy in type 1 diabetes. Trends Mol. Med. 2012, 18:173-181. 10.1016/j.molmed.2012.01.001
11. Grönholm J., Lenardo M.J. Novel diagnostic and therapeutic approaches for autoimmune diabetes - a prime time to treat insulitis as a disease. Clin. Immunol. 2015, 156:109-118. 10.1016/j.clim.2014.11.007
12. Marwaha A.K., Tan S., Dutz J.P. Targeting the IL-17/IFN-γ axis as a potential new clinical therapy for type 1 diabetes. Clin. Immunol. 2014, 154:84-89. 10.1016/j.clim.2014.06.006
13. Prietl B., Treiber G., Pieber T.R., Amrein K. Vitamin D and immune function. Nutrients 2013, 5:2502-2521. 10.3390/nu5072502
14. Gregori S., Giarratana N., Smiroldo S., et al. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374. 10.2337/diabetes.51.5.1367
15. Decallonne B., van Etten E., Overbergh L., et al. 1Alpha,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J. Autoimmun. 2005, 24:281-289.
16. Walter M., Kaupper T., Adler K., et al. No effect of the 1alph,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010, 33:1443-1448. 10.2337/dc09-2297
17. Bizzarri C., Pitocco D., Napoli N., et al. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 2010, 33:1962-1963. 10.2337/dc10-0814
18. Li X., Liao L., Yan X., et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 2009, 3:411-416. 10.1002/dmrr
19. Takiishi T., Ding L., Baeke F., et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes 2014, 63:2026-2036.
20. Prietl B., Pilz S., Wolf M., et al. Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?. Isr. Med. Assoc. J. 2010, 12:136-139.
21. Prietl B., Treiber G., Mader J.K., et al. High-dose cholecalciferol supplementation significantly increases peripheral CD4(+) Tregs in healthy adults without negatively affecting the frequency of other immune cells. Eur. J. Nutr. 2014, 53:751-759. 10.1007/s00394-013-0579-6
22. Gabbay M.A.L., Sato M.N., Finazzo C., et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch. Pediatr. Adolesc. Med. 2012, 166:601-607. 10.1001/archpediatrics.2012.164
23. Glisic-Milosavljevic S., Waukau J., Jailwala P., et al. At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+high T-cell fraction. PLoS One 2007, 2:e146. 10.1371/journal.pone.0000146
24. Hughson A., Bromberg I., Johnson B., et al. Uncoupling of proliferation and cytokines from suppression within the CD4+CD25+Foxp3+ T-cell compartment in the 1st year of human type 1 diabetes. Diabetes 2011, 60:2125-2133. 10.2337/db10-1661
25. Putnam A.L., Brusko T.M., Lee M.R., et al. Expansion of human regulatory T-cells from patients with Type 1 diabetes. Diabetes 2009, 58:652-662. 10.2337/db08-1168.A.L.P
26. Marek-Trzonkowska N., Mysliwiec M., Dobyszuk A., et al. Administration of CD4+CD25highCD127-regulatory T cells preserves β-Cell function in Type1 diabetes in children. Diabetes Care 2012, 35:1817-1820. 10.2337/dc12-0038
27. Marek-Trzonkowskaa N., Myśliwiecb M., Dobyszukc A., et al. Therapy of type 1 diabetes with CD4+CD25highCD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin. Immunol. 2014, 153:23-30.
28. Green E.A., Gorelik L., Mcgregor C.M., et al. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. 2003, 100:10878-10883.
29. You S., Slehoffer G., Barriot S., et al. Unique role of CD4+ CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14580-14585.
30. Baca Jones C., Pagni P.P., Fousteri G., et al. Regulatory T cells control diabetes without compromising acute anti-viral defense. Clin. Immunol. 2014, 153:298-307. 10.1016/j.clim.2014.05.006
31. Monti P., Scirpoli M., Maffi P., et al. Rapamycin monotherapy in patients with type 1. Diabetes 2008, 57:2341-2347. 10.2337/db08-0138.E.B
32. Long S.A., Rieck M., Sanda S., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012, 61:2340-2348. 10.2337/db12-0049
33. Yang C.Y., Leung P.S., Adamopoulos I.E., Gershwin M.E. The implication of vitamin D and autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 2013, 45:217-226. 10.1007/s12016-013-8361-3
34. Jeffery L.E., Burke F., Mura M., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 2009, 183:5458-5467. 10.4049/jimmunol.0803217
35. Jeffery L.E., Wood A.M., Qureshi O.S., et al. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J. Immunol. 2012, 189:5155-5164. 10.4049/jimmunol.1200786
36. Smolders J., Menheere P., Thewissen M., et al. Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2010, 121:243-246. 10.1016/j.jsbmb.2010.03.001
37. Kukreja A., Cost G., Marker J., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002, 109:131-140. 10.1172/JCI200213605.Introduction
38. Brusko T., Wasserfall C., McGrail K., et al. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007, 56:604-612. 10.2337/db06-1248
39. Long S.A., Cerosaletti K., Bollyky P.L., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415. 10.2337/db09-0694
40. Marwaha A.K., Crome S.Q., Panagiotopoulos C., et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 2010, 185:3814-3818. 10.4049/jimmunol.1001860
41. Schmetterer K.G., Neunkirchner A., Pickl W.F. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 2012, 26:2253-2276. 10.1096/fj.11-193672
42. Von Boehmer H., Daniel C. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat. Rev. Drug Discov. 2013, 12:51-63. 10.1038/nrd3683
43. Van Halteren A.G.S., Tysma O.M., van Etten E., et al. 1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J. Autoimmun. 2004, 23:233-239. 10.1016/j.jaut.2004.06.004
44. Chen S., Sims G.P., Chen X.X., et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2011, 179:1634-1647.
45. Glisic-Milosavljevic S., Wang T., Koppen M., et al. Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes. Clin. Exp. Immunol. 2007, 150:75-82. 10.1111/j.1365-2249.2007.03475.x
46. Wolden-Kirk H., Overbergh L., Christesen H.T., et al. Vitamin D and diabetes: its importance for beta cell and immune function. Mol. Cell. Endocrinol. 2011, 347:106-120. 10.1016/j.mce.2011.08.016
47. Ross A.C., Manson J.E., Abrams S.A., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 2011, 96:53-58. 10.1210/jc.2010-2704.